438 related articles for article (PubMed ID: 19574047)
1. Part 1: Structure-Activity Relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase.
Wurz RP; Pettus LH; Xu S; Henkle B; Sherman L; Plant M; Miner K; McBride H; Wong LM; Saris CJ; Lee MR; Chmait S; Mohr C; Hsieh F; Tasker AS
Bioorg Med Chem Lett; 2009 Aug; 19(16):4724-8. PubMed ID: 19574047
[TBL] [Abstract][Full Text] [Related]
2. Part 2: Structure-activity relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase.
Wurz RP; Pettus LH; Henkle B; Sherman L; Plant M; Miner K; McBride HJ; Wong LM; Saris CJ; Lee MR; Chmait S; Mohr C; Hsieh F; Tasker AS
Bioorg Med Chem Lett; 2010 Mar; 20(5):1680-4. PubMed ID: 20138761
[TBL] [Abstract][Full Text] [Related]
3. Discovery of N-substituted pyridinones as potent and selective inhibitors of p38 kinase.
Selness SR; Devraj RV; Monahan JB; Boehm TL; Walker JK; Devadas B; Durley RC; Kurumbail R; Shieh H; Xing L; Hepperle M; Rucker PV; Jerome KD; Benson AG; Marrufo LD; Madsen HM; Hitchcock J; Owen TJ; Christie L; Promo MA; Hickory BS; Alvira E; Naing W; Blevis-Bal R
Bioorg Med Chem Lett; 2009 Oct; 19(20):5851-6. PubMed ID: 19751974
[TBL] [Abstract][Full Text] [Related]
4. 5-amino-pyrazoles as potent and selective p38α inhibitors.
Das J; Moquin RV; Dyckman AJ; Li T; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Newitt JA; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2010 Dec; 20(23):6886-9. PubMed ID: 21035336
[TBL] [Abstract][Full Text] [Related]
5. Discovery and evaluation of 7-alkyl-1,5-bis-aryl-pyrazolopyridinones as highly potent, selective, and orally efficacious inhibitors of p38alpha mitogen-activated protein kinase.
Pettus LH; Wurz RP; Xu S; Herberich B; Henkle B; Liu Q; McBride HJ; Mu S; Plant MH; Saris CJ; Sherman L; Wong LM; Chmait S; Lee MR; Mohr C; Hsieh F; Tasker AS
J Med Chem; 2010 Apr; 53(7):2973-85. PubMed ID: 20218619
[TBL] [Abstract][Full Text] [Related]
6. 3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase.
Pettus LH; Xu S; Cao GQ; Chakrabarti PP; Rzasa RM; Sham K; Wurz RP; Zhang D; Middleton S; Henkle B; Plant MH; Saris CJ; Sherman L; Wong LM; Powers DA; Tudor Y; Yu V; Lee MR; Syed R; Hsieh F; Tasker AS
J Med Chem; 2008 Oct; 51(20):6280-92. PubMed ID: 18817364
[TBL] [Abstract][Full Text] [Related]
7. Discovery of highly selective and potent p38 inhibitors based on a phthalazine scaffold.
Herberich B; Cao GQ; Chakrabarti PP; Falsey JR; Pettus L; Rzasa RM; Reed AB; Reichelt A; Sham K; Thaman M; Wurz RP; Xu S; Zhang D; Hsieh F; Lee MR; Syed R; Li V; Grosfeld D; Plant MH; Henkle B; Sherman L; Middleton S; Wong LM; Tasker AS
J Med Chem; 2008 Oct; 51(20):6271-9. PubMed ID: 18817365
[TBL] [Abstract][Full Text] [Related]
8. The discovery of (R)-2-(sec-butylamino)-N-(2-methyl-5-(methylcarbamoyl)phenyl) thiazole-5-carboxamide (BMS-640994)-A potent and efficacious p38alpha MAP kinase inhibitor.
Hynes J; Wu H; Pitt S; Shen DR; Zhang R; Schieven GL; Gillooly KM; Shuster DJ; Taylor TL; Yang X; McIntyre KW; McKinnon M; Zhang H; Marathe PH; Doweyko AM; Kish K; Kiefer SE; Sack JS; Newitt JA; Barrish JC; Dodd J; Leftheris K
Bioorg Med Chem Lett; 2008 Mar; 18(6):1762-7. PubMed ID: 18313298
[TBL] [Abstract][Full Text] [Related]
9. Design of potent and selective 2-aminobenzimidazole-based p38alpha MAP kinase inhibitors with excellent in vivo efficacy.
de Dios A; Shih C; López de Uralde B; Sánchez C; del Prado M; Martín Cabrejas LM; Pleite S; Blanco-Urgoiti J; Lorite MJ; Nevill CR; Bonjouklian R; York J; Vieth M; Wang Y; Magnus N; Campbell RM; Anderson BD; McCann DJ; Giera DD; Lee PA; Schultz RM; Li LC; Johnson LM; Wolos JA
J Med Chem; 2005 Apr; 48(7):2270-3. PubMed ID: 15801819
[TBL] [Abstract][Full Text] [Related]
10. Benzothiazole based inhibitors of p38alpha MAP kinase.
Liu C; Lin J; Pitt S; Zhang RF; Sack JS; Kiefer SE; Kish K; Doweyko AM; Zhang H; Marathe PH; Trzaskos J; Mckinnon M; Dodd JH; Barrish JC; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2008 Mar; 18(6):1874-9. PubMed ID: 18296051
[TBL] [Abstract][Full Text] [Related]
11. 2,4-Diaminopyrimidine MK2 inhibitors. Part II: Structure-based inhibitor optimization.
Harris CM; Ericsson AM; Argiriadi MA; Barberis C; Borhani DW; Burchat A; Calderwood DJ; Cunha GA; Dixon RW; Frank KE; Johnson EF; Kamens J; Kwak S; Li B; Mullen KD; Perron DC; Wang L; Wishart N; Wu X; Zhang X; Zmetra TR; Talanian RV
Bioorg Med Chem Lett; 2010 Jan; 20(1):334-7. PubMed ID: 19926477
[TBL] [Abstract][Full Text] [Related]
12. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitors.
Hynes J; Dyckman AJ; Lin S; Wrobleski ST; Wu H; Gillooly KM; Kanner SB; Lonial H; Loo D; McIntyre KW; Pitt S; Shen DR; Shuster DJ; Yang X; Zhang R; Behnia K; Zhang H; Marathe PH; Doweyko AM; Tokarski JS; Sack JS; Pokross M; Kiefer SE; Newitt JA; Barrish JC; Dodd J; Schieven GL; Leftheris K
J Med Chem; 2008 Jan; 51(1):4-16. PubMed ID: 18072718
[TBL] [Abstract][Full Text] [Related]
14. Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as orally bioavailable and highly selective inhibitors of p38α mitogen-activated protein kinase.
Goldstein DM; Soth M; Gabriel T; Dewdney N; Kuglstatter A; Arzeno H; Chen J; Bingenheimer W; Dalrymple SA; Dunn J; Farrell R; Frauchiger S; La Fargue J; Ghate M; Graves B; Hill RJ; Li F; Litman R; Loe B; McIntosh J; McWeeney D; Papp E; Park J; Reese HF; Roberts RT; Rotstein D; San Pablo B; Sarma K; Stahl M; Sung ML; Suttman RT; Sjogren EB; Tan Y; Trejo A; Welch M; Weller P; Wong BR; Zecic H
J Med Chem; 2011 Apr; 54(7):2255-65. PubMed ID: 21375264
[TBL] [Abstract][Full Text] [Related]
15. 5-Cyanopyrimidine derivatives as a novel class of potent, selective, and orally active inhibitors of p38alpha MAP kinase.
Liu C; Wrobleski ST; Lin J; Ahmed G; Metzger A; Wityak J; Gillooly KM; Shuster DJ; McIntyre KW; Pitt S; Shen DR; Zhang RF; Zhang H; Doweyko AM; Diller D; Henderson I; Barrish JC; Dodd JH; Schieven GL; Leftheris K
J Med Chem; 2005 Oct; 48(20):6261-70. PubMed ID: 16190753
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and structure-activity relationships of aminopyridine N-oxides, a novel scaffold for the potent and selective inhibition of p38 mitogen activated protein kinase.
Lumeras W; Caturla F; Vidal L; Esteve C; Balagué C; Orellana A; Domínguez M; Roca R; Huerta JM; Godessart N; Vidal B
J Med Chem; 2009 Sep; 52(17):5531-45. PubMed ID: 19678708
[TBL] [Abstract][Full Text] [Related]
17. Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.
Das J; Moquin RV; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2008 Apr; 18(8):2652-7. PubMed ID: 18359226
[TBL] [Abstract][Full Text] [Related]
18. Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase.
Goldstein DM; Alfredson T; Bertrand J; Browner MF; Clifford K; Dalrymple SA; Dunn J; Freire-Moar J; Harris S; Labadie SS; La Fargue J; Lapierre JM; Larrabee S; Li F; Papp E; McWeeney D; Ramesha C; Roberts R; Rotstein D; San Pablo B; Sjogren EB; So OY; Talamas FX; Tao W; Trejo A; Villasenor A; Welch M; Welch T; Weller P; Whiteley PE; Young K; Zipfel S
J Med Chem; 2006 Mar; 49(5):1562-75. PubMed ID: 16509574
[TBL] [Abstract][Full Text] [Related]
19. Pyrazoloheteroaryls: novel p38alpha MAP kinase inhibiting scaffolds with oral activity.
Revesz L; Blum E; Di Padova FE; Buhl T; Feifel R; Gram H; Hiestand P; Manning U; Neumann U; Rucklin G
Bioorg Med Chem Lett; 2006 Jan; 16(2):262-6. PubMed ID: 16249085
[TBL] [Abstract][Full Text] [Related]
20. Discovery of pyrrolo[2,1-f][1,2,4]triazine C6-ketones as potent, orally active p38α MAP kinase inhibitors.
Dyckman AJ; Li T; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly KM; Shuster DJ; Doweyko AM; Sack JS; Kish K; Kiefer SE; Newitt JA; Zhang H; Marathe PH; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2011 Aug; 21(15):4633-7. PubMed ID: 21705217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
